[go: up one dir, main page]

MA49726B1 - Formulation d'anticorps anti-cgrp - Google Patents

Formulation d'anticorps anti-cgrp

Info

Publication number
MA49726B1
MA49726B1 MA49726A MA49726A MA49726B1 MA 49726 B1 MA49726 B1 MA 49726B1 MA 49726 A MA49726 A MA 49726A MA 49726 A MA49726 A MA 49726A MA 49726 B1 MA49726 B1 MA 49726B1
Authority
MA
Morocco
Prior art keywords
antibody formulation
cgrp antibody
headaches
episodic
chronic
Prior art date
Application number
MA49726A
Other languages
English (en)
Other versions
MA49726A (fr
Inventor
Anant N. SHARMA
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of MA49726A publication Critical patent/MA49726A/fr
Publication of MA49726B1 publication Critical patent/MA49726B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne des formulations pharmaceutiques d'anticorps anti-CGRP, et leurs procédés d'utilisation, lesdites formulations étant utiles dans le traitement des migraines, des maux de tête épisodiques, des maux de tête chroniques, des céphalées en grappe chroniques, et des céphalées en grappe épisodiques.
MA49726A 2015-06-17 2016-06-08 Formulation d'anticorps anti-cgrp MA49726B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562180905P 2015-06-17 2015-06-17
EP16729483.4A EP3310809B1 (fr) 2015-06-17 2016-06-08 Formulation d'anticorps anti-cgrp
PCT/US2016/036407 WO2016205037A1 (fr) 2015-06-17 2016-06-08 Formulation d'anticorps anti-cgrp

Publications (2)

Publication Number Publication Date
MA49726A MA49726A (fr) 2020-06-10
MA49726B1 true MA49726B1 (fr) 2025-02-28

Family

ID=56131672

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49726A MA49726B1 (fr) 2015-06-17 2016-06-08 Formulation d'anticorps anti-cgrp

Country Status (31)

Country Link
US (3) US11498959B2 (fr)
EP (2) EP3310809B1 (fr)
JP (1) JP6438599B2 (fr)
KR (1) KR102000867B1 (fr)
CN (3) CN107787229A (fr)
AR (2) AR104847A1 (fr)
AU (1) AU2016280555B2 (fr)
BR (1) BR112017023374A2 (fr)
CA (1) CA2984185A1 (fr)
DK (1) DK3310809T3 (fr)
EA (1) EA037580B1 (fr)
ES (1) ES3000607T3 (fr)
FI (1) FI3310809T3 (fr)
HR (1) HRP20241660T1 (fr)
HU (1) HUE069368T2 (fr)
IL (2) IL292562A (fr)
JO (1) JO3772B1 (fr)
LT (1) LT3310809T (fr)
MA (1) MA49726B1 (fr)
MD (1) MD3310809T2 (fr)
MX (1) MX395147B (fr)
MY (1) MY184266A (fr)
NZ (1) NZ737046A (fr)
PL (1) PL3310809T3 (fr)
PT (1) PT3310809T (fr)
RS (1) RS66243B1 (fr)
SI (1) SI3310809T1 (fr)
TW (1) TWI725973B (fr)
UA (1) UA120881C2 (fr)
WO (1) WO2016205037A1 (fr)
ZA (1) ZA201707324B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
SI3119431T1 (sl) 2014-03-21 2024-06-28 Teva Pharmaceuticals International Gmbh Antagonistična protitelesa, usmerjena proti peptidu, povezanemu z genom za kalcitonin, in postopki za uporabo le-teh
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
MX2019003338A (es) * 2016-09-23 2019-09-26 Teva Pharmaceuticals Int Gmbh Tratamiento de cefalea en racimos.
PE20191148A1 (es) 2016-09-23 2019-09-02 Teva Pharmaceuticals Int Gmbh Tratamiento de la migrana refractaria
US10766952B2 (en) 2017-03-02 2020-09-08 Beth Israel Deaconess Medical Center, Inc. Methods for reducing migraine frequency in a subject in need thereof
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
KR20200139720A (ko) * 2018-04-02 2020-12-14 암젠 인크 에레누맙 조성물 및 이의 용도
WO2019231800A1 (fr) * 2018-05-31 2019-12-05 Eli Lilly And Company Anticorps anti-cgrp pour le traitement des migraines liées aux menstruations
KR20250106313A (ko) * 2018-09-20 2025-07-09 테바 파마슈티컬스 인터내셔널 게엠베하 에이징된 사전 충전형 주사기 및 자동 주입기를 위한 주입 스프링
CR20210373A (es) 2019-01-08 2021-08-19 H Lundbeck As Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
CA3133571A1 (fr) * 2019-05-02 2020-11-05 Roger K. Cady Traitement de cephalees a l'aide d'anticorps anti-cgrp
AU2020202454A1 (en) 2020-04-06 2021-10-21 H. Lundbeck A/S Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies
EP4301362A1 (fr) 2021-03-02 2024-01-10 CGRP Diagnostics GmbH Traitement et/ou réduction de l'apparition de migraine
US20250109188A1 (en) 2021-08-24 2025-04-03 Cgrp Diagnostics Gmbh Preventative treatment of migraine

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007510A1 (fr) 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprenant une formulation d'un facteur de coagulation viii, procede pour sa preparation et utilisation d'un agent tensioactif comme stabilisateur
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
NZ532896A (en) * 2001-11-08 2007-08-31 Pdl Biopharma Inc Stable liquid pharmaceutical formulation of IGG antibodies including daclizumab and fontolizumab
WO2004071439A2 (fr) 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Preparation d'immunoglobuline et son procede de production
CN101111264A (zh) 2005-01-28 2008-01-23 惠氏公司 稳定化的液体多肽制剂
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
JP2006249083A (ja) * 2005-03-08 2006-09-21 Pharmacia & Upjohn Co Llc 抗ｍ−ｃｓｆ抗体組成物
AU2006344395B2 (en) * 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
EP1957106B2 (fr) 2005-11-14 2019-07-24 Teva Pharmaceuticals International GmbH Anticorps antagonistes orientes contre un peptide lie au gene de la calcitonine, et procedes d'utilisation correspondants
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
CA2671968A1 (fr) * 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Formulation parenterale d'anticorps anti-peptide abeta
AR064826A1 (es) * 2007-01-09 2009-04-29 Wyeth Corp Formulaciones de anticuerpos anti-il-13 y usos de los mismos. dispositivos, parche y jeringa
CA2681743A1 (fr) * 2007-03-22 2008-09-25 Imclone Llc Formulations d'anticorps stables
CA2682170A1 (fr) 2007-03-30 2008-10-09 Medimmune, Llc Anticorps presentant des profils de desamidation reduits
CN101970000A (zh) * 2007-04-18 2011-02-09 杨森阿尔茨海默氏症免疫治疗公司 脑淀粉样血管病的预防和治疗
EP3329911A1 (fr) * 2008-09-19 2018-06-06 Pfizer Inc Composition, liquide et stable, à base d'anticorps
US9393304B2 (en) 2008-10-29 2016-07-19 Ablynx N.V. Formulations of single domain antigen binding molecules
CN102438652B (zh) * 2008-11-12 2014-08-13 米迪缪尼有限公司 抗体制剂
BRPI0921320A2 (pt) * 2008-11-28 2018-05-22 Abbott Laboratories composições de anticorpo estáveis e métodos para estabilizar os mesmos
EP2196476A1 (fr) 2008-12-10 2010-06-16 Novartis Ag Formulation d'anticorps
CN102413839A (zh) * 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3330B1 (ar) * 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
MX350142B (es) * 2010-08-23 2017-08-28 Wyeth Llc * Formulaciones estables de antigenos rlp2086 de neisseria meningitidis.
MX341076B (es) * 2011-03-31 2016-08-04 Merck Sharp & Dohme Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
SG10201604040PA (en) * 2011-05-20 2016-07-28 Alderbio Holdings Llc Anti-cgrp compositions and use thereof
TW201326207A (zh) 2011-10-24 2013-07-01 Abbvie Inc 抗ｔｎｆ免疫結合物
US20140227250A1 (en) * 2012-08-23 2014-08-14 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
JP2016505633A (ja) * 2013-01-24 2016-02-25 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ ＴＮＦα抗原結合性タンパク質
SI3119431T1 (sl) * 2014-03-21 2024-06-28 Teva Pharmaceuticals International Gmbh Antagonistična protitelesa, usmerjena proti peptidu, povezanemu z genom za kalcitonin, in postopki za uporabo le-teh
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
WO2017074428A1 (fr) * 2015-10-30 2017-05-04 Eli Lilly And Company Anticorps bispécifiques anti-cgrp/anti-il-23 et leurs utilisations

Also Published As

Publication number Publication date
HUE069368T2 (hu) 2025-02-28
JP2018517727A (ja) 2018-07-05
KR20180002858A (ko) 2018-01-08
AR104847A1 (es) 2017-08-16
MY184266A (en) 2021-03-30
HRP20241660T1 (hr) 2025-02-14
US20180134772A1 (en) 2018-05-17
NZ737046A (en) 2019-09-27
CA2984185A1 (fr) 2016-12-22
MA49726A (fr) 2020-06-10
ES3000607T3 (en) 2025-03-03
ZA201707324B (en) 2020-01-29
EA201792359A1 (ru) 2018-05-31
BR112017023374A2 (pt) 2018-07-24
KR102000867B1 (ko) 2019-07-16
SI3310809T1 (sl) 2025-03-31
US20230159628A1 (en) 2023-05-25
US20220112277A1 (en) 2022-04-14
EP4470557A3 (fr) 2025-02-26
MX2017016199A (es) 2018-03-01
EP4470557A2 (fr) 2024-12-04
WO2016205037A1 (fr) 2016-12-22
CN107787229A (zh) 2018-03-09
JP6438599B2 (ja) 2018-12-19
JO3772B1 (ar) 2021-01-31
IL255443B (en) 2022-06-01
US11498959B2 (en) 2022-11-15
RS66243B1 (sr) 2024-12-31
TWI725973B (zh) 2021-05-01
PL3310809T3 (pl) 2025-01-27
IL255443A0 (en) 2017-12-31
IL292562A (en) 2022-06-01
CN118356393A (zh) 2024-07-19
AR133453A2 (es) 2025-10-01
AU2016280555A1 (en) 2017-11-16
LT3310809T (lt) 2025-01-10
UA120881C2 (uk) 2020-02-25
MX395147B (es) 2025-03-24
EP3310809B1 (fr) 2024-10-16
DK3310809T3 (da) 2024-12-02
CN114948847A (zh) 2022-08-30
PT3310809T (pt) 2024-12-16
HK1245813A1 (en) 2018-08-31
TW201711697A (zh) 2017-04-01
EP3310809A1 (fr) 2018-04-25
EA037580B1 (ru) 2021-04-16
MD3310809T2 (ro) 2025-03-31
FI3310809T3 (fi) 2024-12-07
AU2016280555B2 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
MA49726B1 (fr) Formulation d'anticorps anti-cgrp
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
SA519401522B1 (ar) Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات
MA53356B1 (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
MA37538A2 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
EP3386536A4 (fr) Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
EP3645742A4 (fr) Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation
MA40513A (fr) Conjugués médicament-anticorps anti-cdh6
MA46770A (fr) Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA40682B1 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MA42971A (fr) Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
MX381232B (es) Formulación de anticuerpos.
EA201792616A1 (ru) Средства, пути применения и способы лечения синуклеопатии
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
MA40576A (fr) Anticorps et immunoconjugués anti-her2
EA201791093A1 (ru) Антитела к cd47, способы и применение
EA201890278A1 (ru) Антитела к pd-l1
EA201690618A1 (ru) Ингибиторы тирозинкиназы брутона
MA38554A3 (fr) Anticorps bispécifiques dirigés contre fap et dr5, anticorps spécifiques dirigés contre dr5 et leurs procédés d'utilisation
EA201792182A1 (ru) Композиции и способы для лечения анемии
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
MA35898B1 (fr) Anticorps anti-lrp5 et leurs procédés d'utilisation
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201592203A1 (ru) Способы лечения таупатии